Nab-paclitaxel in patients with metastatic melanoma

Roberto A. Leon-Ferre, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic melanoma, that are now leading the way for other malignancies. With the advent of these new therapeutic options, chemotherapy is no longer favored as a first line strategy in metastatic melanoma, but continues to play a role in the salvage treatment of patients that have become refractory to immune-based or targeted therapies. Nab-paclitaxel, a solvent-free alternative to solvent-based paclitaxel, has shown in several trials to be active in metastatic melanoma. Herein, we summarize the role of nab-paclitaxel in the management of patients with advanced melanoma.

Original languageEnglish (US)
Pages (from-to)1371-1377
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume15
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Melanoma
Salvage Therapy
Therapeutics
Paclitaxel
130-nm albumin-bound paclitaxel
Neoplasms
Drug Therapy
Skin

Keywords

  • albumin-bound paclitaxel
  • cremophore free paclitaxel
  • Melanoma
  • nab-paclitaxel
  • solvent-free paclitaxel
  • taxanes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Nab-paclitaxel in patients with metastatic melanoma. / Leon-Ferre, Roberto A.; Markovic, Svetomir Nenad.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 12, 02.12.2015, p. 1371-1377.

Research output: Contribution to journalArticle

@article{1c0382a2ad2449bea0183f2050aadf32,
title = "Nab-paclitaxel in patients with metastatic melanoma",
abstract = "Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic melanoma, that are now leading the way for other malignancies. With the advent of these new therapeutic options, chemotherapy is no longer favored as a first line strategy in metastatic melanoma, but continues to play a role in the salvage treatment of patients that have become refractory to immune-based or targeted therapies. Nab-paclitaxel, a solvent-free alternative to solvent-based paclitaxel, has shown in several trials to be active in metastatic melanoma. Herein, we summarize the role of nab-paclitaxel in the management of patients with advanced melanoma.",
keywords = "albumin-bound paclitaxel, cremophore free paclitaxel, Melanoma, nab-paclitaxel, solvent-free paclitaxel, taxanes",
author = "Leon-Ferre, {Roberto A.} and Markovic, {Svetomir Nenad}",
year = "2015",
month = "12",
day = "2",
doi = "10.1586/14737140.2015.1110024",
language = "English (US)",
volume = "15",
pages = "1371--1377",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Nab-paclitaxel in patients with metastatic melanoma

AU - Leon-Ferre, Roberto A.

AU - Markovic, Svetomir Nenad

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic melanoma, that are now leading the way for other malignancies. With the advent of these new therapeutic options, chemotherapy is no longer favored as a first line strategy in metastatic melanoma, but continues to play a role in the salvage treatment of patients that have become refractory to immune-based or targeted therapies. Nab-paclitaxel, a solvent-free alternative to solvent-based paclitaxel, has shown in several trials to be active in metastatic melanoma. Herein, we summarize the role of nab-paclitaxel in the management of patients with advanced melanoma.

AB - Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic melanoma, that are now leading the way for other malignancies. With the advent of these new therapeutic options, chemotherapy is no longer favored as a first line strategy in metastatic melanoma, but continues to play a role in the salvage treatment of patients that have become refractory to immune-based or targeted therapies. Nab-paclitaxel, a solvent-free alternative to solvent-based paclitaxel, has shown in several trials to be active in metastatic melanoma. Herein, we summarize the role of nab-paclitaxel in the management of patients with advanced melanoma.

KW - albumin-bound paclitaxel

KW - cremophore free paclitaxel

KW - Melanoma

KW - nab-paclitaxel

KW - solvent-free paclitaxel

KW - taxanes

UR - http://www.scopus.com/inward/record.url?scp=84949320076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949320076&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1110024

DO - 10.1586/14737140.2015.1110024

M3 - Article

VL - 15

SP - 1371

EP - 1377

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -